Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.
Chan, AY; Leiding, JW; Liu, X; Logan, BR; Burroughs, LM; Allenspach, EJ; Skoda-Smith, S; Uzel, G; Notarangelo, LD; Slatter, M; et al.
Frontiers in Immunology.
2020;
11.
The Variable Genomic NK Cell Receptor Locus Is a Key Determinant of CD4+ T Cell Responses During Viral Infection.
Raynor, J; Lin, A; Hummel, SA; Lampe, K; Jordan, M; Hoebe, K; Hildeman, DA.
Frontiers in Immunology.
2020;
11.
CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells.
Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al.
Biology of Blood and Marrow Transplantation.
2020;
26:1-6.
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
Jordan, MB; Allen, CE; Greenberg, J; Henry, M; Hermiston, ML; Kumar, A; Hines, M; Eckstein, O; Ladisch, S; Nichols, KE; et al.
Pediatric Blood and Cancer.
2019;
66.
TNF-mediated compensatory immunity to mycobacterium avium in the absence of macrophage activation by IFN-γ.
Resende, M; Cardoso, MS; Frois-Martins, R; Borges, M; Jordan, MB; Castro, AG; Appelberg, R.
Journal of immunology (Baltimore, Md. : 1950).
2019;
203:2451-2458.
Identifying and targeting pathogenic PI3K/AKT/ mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum, DC; Langan, R; Japp, AS; Partridge, HL; Pierson, SK; Singh, A; Arenas, DJ; Ruth, JR; Nabel, CS; Stone, K; et al.
Journal of Clinical Investigation.
2019;
130:4451-4463.
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
La Rosee, P; Horne, A; Hines, M; Greenwood, TV B; Machowicz, R; Berliner, N; Birndt, S; Gil-Herrera, J; Girschikofsky, M; Jordan, MB; et al.
Blood.
2019;
133:2465-2477.
CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez, JE; Baxter, RM; Kong, DS; Tobin, R; McCarter, M; Routes, JM; Verbsky, J; Jordan, MB; Dutmer, CM; Hsieh, EW Y.
Frontiers in Immunology.
2019;
10.
Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition.
Eckstein, OS; Visser, J; Rodriguez-Galindo, C; Allen, CE; Zinn, DJ; Peckham-Gregory, EC; Lin, H; Henry, MM; Morland, B; Levy, CF; et al.
Blood.
2019;
133:1691-1694.
Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.
Dorjbal, B; Stinson, JR; Ma, CA; Weinreich, MA; Miraghazadeh, B; Hartberger, JM; Frey-Jakobs, S; Weidinger, S; Moebus, L; Franke, A; et al.
Journal of Allergy and Clinical Immunology.
2019;
143:1482-1495.